iPLATO Healthcare

iplato.com

iPLATO Healthcare is a London based innovation company dedicated to Health Tech since 2006. iPLATO’s evidence based mobile health solutions have proven to improve patient access to healthcare, to enable powerful health promotion targeted at people at risk and to support people with long term conditions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

news image

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More

Industry Outlook

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

news image

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

news image

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More
news image

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More
news image

Industry Outlook

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More
news image

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More
news image

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

Whitepaper

resource image

Industrial Impact

Bruker Services & Software

Video

resource image

Industrial Impact, Industry Outlook

Are Nitrosamines a Concern for Biologic Manufacturers?

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

Whitepaper

resource image

Industrial Impact

Bruker Services & Software

Video

resource image

Industrial Impact, Industry Outlook

Are Nitrosamines a Concern for Biologic Manufacturers?

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us